What were the main drivers of sales growth in 2007?

Sales growth in 2007 was primarily driven by the Critical Care segment, particularly the FloTrac system and other hemodynamic monitoring products, along with the Heart Valve Therapy segment, led by premium products like the PERIMOUNT Magna valves. International sales also contributed significantly, bolstered by favorable currency exchange rates.

What is the company's strategy regarding its product portfolio?

Edwards Lifesciences is strategically focusing on its core heart valve and critical care businesses. This is evidenced by the divestiture of the LifeStent peripheral vascular product line in early 2008 and the acquisition of CardioVations to bolster its minimally invasive heart valve surgery offerings.

How is the company investing in future growth?

The company is making substantial investments in research and development, with a key focus on developing transcatheter heart valve replacement and repair technologies, such as the Edwards SAPIEN THV aortic valve replacement system. These minimally invasive technologies target a significant market opportunity in treating advanced cardiovascular disease.

What is the company's financial health and capital management strategy?

Edwards Lifesciences demonstrated strong financial health with increased net sales and a robust operating cash flow of $210.2 million in 2007. The company actively manages its capital through stock repurchase programs and maintains significant liquidity through its revolving credit facility, indicating a commitment to shareholder value and operational flexibility.

EW 10-K FY2007 Annual Report — Revenue, Net Income, EPS

Summary

Edwards Lifesciences Corporation's 2007 10-K filing highlights a year of solid growth, with net sales increasing by 5.2% to $1.09 billion. The company demonstrated strong performance in its Critical Care segment, which saw a significant 13.7% increase in sales, driven by its innovative FloTrac system. Heart Valve Therapy also showed healthy growth, up 4.9%, supported by its premium PERIMOUNT Magna valves. However, the Cardiac Surgery Systems segment experienced a notable decline of 33.1%, primarily due to the divestiture of the Brazil-based perfusion product line and the exit from the TMR product line. The company continues to invest heavily in research and development, with a significant portion allocated to its next-generation transcatheter heart valve technologies, aiming to capture the substantial market opportunity in less invasive cardiovascular treatments. Financially, Edwards Lifesciences maintains a strong liquidity position with robust operating cash flow, and it actively manages its capital structure through stock repurchases and debt management. The company is well-positioned to navigate the competitive healthcare landscape, driven by its focus on innovation and expanding its minimally invasive offerings.

Key Highlights

1Net sales grew by 5.2% to $1.09 billion in 2007, demonstrating continued revenue expansion.

2Critical Care segment experienced robust growth of 13.7%, driven by the FloTrac system and other hemodynamic monitoring products.

3Heart Valve Therapy sales increased by 4.9%, supported by premium products like the PERIMOUNT Magna valves.

4Cardiac Surgery Systems segment saw a significant decline of 33.1% due to divestitures and product line exits.

5Significant R&D investment of $122.3 million (11.2% of sales) focused on transcatheter heart valve technologies.

6The company ended the year with a strong cash position of $141.8 million and ample liquidity through its revolving credit facility.

7Edwards Lifesciences sold its LifeStent peripheral vascular product line in January 2008 to focus on core businesses.

Edwards Lifesciences Corp Annual Report, Year Ended Dec 31, 2007

Summary

Key Highlights

Frequently Asked Questions